Stevanato Group S.p.A. (STVN)is a renowned global provider of drug containment, drug delivery, and diagnostic solutions aimed at improving the health and well-being of patients. The company has its roots in Italy and was founded by Sergio Stevanato in 1949 where it started as a small artisan workshop producing glassware and components for the lighting industry. Since then, the company has significantly transformed and evolved into a leading provider that serves the pharmaceutical and healthcare industry on a global scale.
The company currently operates through two interconnected business branches - Pharmaceutical Systems and Engineering Systems. The former deals with the production and distribution of glass containers, such as vials and syringes, while the latter is responsible for providing machines and technology solutions for glass forming and inspection.
Stevanato Group S.p.A. has benefitted enormously from its long-lasting partnerships with pharmaceutical and biotechnology companies. It is the supplier behind innovative drug delivery systems, rigid sterile containers, and integrated analytical lab services. Through its offerings, Stevanato Group aims to ensure the safest and most efficient delivery of drugs to patients and has hence contributed broadly to global health outcomes.
The company's commitment to quality and safety is underlined by its numerous certifications, including ISO standards, which demonstrate adherences to regulatory requirements and international quality systems. This emphasis on quality has seen the company establish manufacturing facilities and commercial offices in 14 countries across Europe, the Americas, and Asia, reflecting its truly global presence.
Stevanato Group is also actively involved in research and development initiatives, which include collaborations with research institutions and pharmaceutical companies to advance the frontiers of healthcare. The company has a dedicated team of professionals working on various patents and projects developing cutting-edge technologies, further cementing Stevanato Group’s reputation as an innovative leader in the industry.
With its rich history, vast global presence, and commitment to delivering high-quality healthcare solutions, Stevanato Group S.p.A. continually demonstrates its ambition to shape the future of the pharmaceutical and healthcare industries.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article from Stock Traders Daily analyzes Stevanato Group S.p.a. (NASDAQ: STVN), noting a potential shift from persistent mid to long-term weakness towards strong near-term sentiment. It highlights compelling upside potential as no resistance levels remain above the current price. The analysis provides AI-generated institutional trading strategies for various risk profiles, including long, breakout, and short positions with specific entry, target, and stop-loss parameters, alongside a multi-timeframe signal breakdown.
Squarepoint Ops LLC significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by purchasing 109,702 additional shares, bringing its total holdings to 193,311 shares worth approximately $3.49 million. Other institutional investors like Wellington Management and Confluence Investment Management also established new positions, reflecting growing interest in the company. Despite slightly missing consensus EPS estimates for its latest quarter, analyst sentiment remains favorable, with the company holding a "Moderate Buy" rating.
Wellington Management Group LLP has acquired a new stake in Stevanato Group S.p.A., purchasing over 1.25 million shares worth approximately $22.6 million. This investment gives Wellington Management Group a 0.41% stake in the company, with other institutional investors also increasing their holdings. Analysts generally maintain a "Buy" rating for Stevanato Group, despite the company slightly missing its last quarterly earnings per share consensus.
Stevanato Group S.p.A. (NYSE:STVN) has received a consensus "Buy" rating from six brokerages, with two analysts rating it a "hold," two a "buy," and two a "strong buy." Recent analyst actions include an upgrade to "strong buy" by TD Cowen and an "outperform" rating initiation by Wolfe Research with a €21 price target. Despite reporting slightly lower-than-expected quarterly EPS of €0.14 against a €0.15 consensus, analysts anticipate full-year EPS of approximately €0.71.
Bank of America Corp DE significantly reduced its stake in Stevanato Group S.p.A. by selling 784,125 shares, retaining 163,149 shares valued at $2.24 million. Despite this, analyst sentiment for Stevanato Group remains generally positive, with an average "Buy" rating and a target price of $21 from Wolfe Research. The company recently reported quarterly EPS of €0.14, slightly below estimates, on revenues of €302 million.
Riverwater Partners, an investment management company, believes the market has overreacted to Stevanato Group (STVN) following the launch of oral GLP-1s, creating an attractive entry point. The firm initiated a position in STVN, arguing that an expanding GLP-1 market and varying use cases will continue to necessitate injectable forms, especially with 25% of 2025's approved drugs being biologics requiring injectable devices. Riverwater notes STVN's attractive valuation of 12.5x FY2026E EBITDA compared to its historical multiple of 20x and peers.
Ranger Investment Management L.P. has made a new $21.44 million investment in Stevanato Group S.p.A. (NYSE:STVN), acquiring 1.19 million shares, which constitutes about 0.39% of the company. Stevanato Group reported quarterly revenue of €302 million and earnings of €0.14 per share, slightly below analyst estimates. Analysts currently hold an overall "Buy" rating for the stock, despite recent insider sales primarily due to tax obligations.
Morningstar has initiated coverage on Stevanato Group S.p.A. (STVN) with a narrow moat rating and a fair value estimate of USD 21.10. The shares are currently considered fairly valued at their current price of 21.52. Stevanato Group provides glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries through its Biopharmaceutical and Diagnostic Solutions segment.